Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

New England Journal of Medicine

Volumn 378, Issue 26, 2018, Pages 2486-2496

  Castro, M ^a   Corren, J ^b   Pavord, I D ^d   Maspero, J ^e   Wenzel, S ^f   Rabe, K F ^g,h   Busse, W W ⁱ   Ford, L ^j   Sher, L ^c   FitzGerald, J M ^k   Katelaris, C ^l   Tohda, Y ^m   Zhang, B ⁿ   Staudinger, H ⁿ   Pirozzi, G ⁿ   Amin, N ^o   Ruddy, M ^o   Akinlade, B ^o   Khan, A ⁿ   Chao, J ^o   Martincova, R ^p   Graham, N M H ^o   Hamilton, J D ^o   Swanson, B N ⁿ   Stahl, N ^o   Yancopoulos, G D ^o   Teper, A ⁿ   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Peninsula Research Institute   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CABA   (Argentina)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g LungenClinic Grosshansdorf   (Germany)

^h UNIVERSITY OF KIEL   (Germany)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j Asthma and Allergy Center   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l UNIVERSITY OF WESTERN SYDNEY   (Australia)

^m KINKI UNIVERSITY   (Japan)

ⁿ SANOFI   (France)

^o REGENERON PHARMACEUTICALS INC   (United States)

^p Sanofi Pasteur   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DUPILUMAB; GLUCOCORTICOID; PLACEBO; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHILD; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPEREOSINOPHILIA; INFLUENZA; INJECTION SITE REACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; EOSINOPHILIA; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENTION TO TREAT ANALYSIS; INTERLEUKIN-13; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-4; YOUNG ADULT;

EID: 85049153036     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1804092     Document Type: Article

References (20)

1. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-44.
2. Hermosa JL, Sanchez CB, Rubio MC, Minguez MM, Walther JL. Factors associated with the control of severe asthma. J Asthma 2010; 47: 124-30.
3. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100: 1139-51.
4. Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018; 73: 116-24.
5. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-200.
6. Fahy JV. Type 2 inflammation in asthma - present in most, absent in many. Nat Rev Immunol 2015; 15: 57-65.
7. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: Current knowledge and therapeutic implications. Clin Exp Allergy 2017; 47: 161-75.
8. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 2017; 13: 425-37.
9. Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014; 111: 5147-52.
10. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo- controlled, phase 3 trial. Lancet 2017; 389: 2287-303.
11. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-48.
12. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52.
13. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ß2 agonist: A randomised double-blind placebocontrolled pivotal phase 2b dose-ranging trial. Lancet 2016; 388: 31-44.
14. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid- dependent severe asthma. N Engl J Med 2018;378:2475-85.
15. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2015 (http://ginasthma .org/wp-content/uploads/2016/01/GINA-Report -2015-Aug11-1 .pdf).
16. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553-8.
17. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115: 1265-70.
18. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
19. Coumou H, Westerhof GA, de Nijs SB, Zwinderman AH, Bel EH. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J 2018; 51(2): 1701785.
20. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013; 12: 117-29.